Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Licenses MGB, Eclipse Technologies to Celera Diagnostics

NEW YORK, Feb. 11 (GenomeWeb News) - Epoch Biosciences of Bothell, Wash., today announced a licensing agreement with Celera Diagnostics.


Epoch will license its MGB and Eclipse Dark Quencher technologies into Celera Diagnostics' products for selected infectious diseases, the company said in a statement.


The license allows Celera Diagnostics to manufacture, sell and distribute TaqMan probes that utilize Epoch's minor groove binder and quencher in selected products. Under the license agreement, Epoch will receive license fees and royalties on sales of such licensed products to end users. Additional terms of the agreement were not disclosed.


Celera Diagnostics is a joint venture between the Celera Genomics and Applied Biosystems of Applera.


The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.